|Genotypic Testing for HIV Drug Resistance: Related Resources|
|Content reviewed April 2009|
| Related Knowledge Base Chapters|
| Journal Articles|
|HIV-1 genetic diversity and transmitted resistance in health care settings in Maputo, Mozambigue|
Bartolo I, Casanovas J, Bastos R, et al. J Acquir Immune Def Syndr. 2009;51:323-31. Includes commentary from the UCSF Institute for Global Health.
|Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use|
Le T, Chiarella J, Simen BB, et al. PLoS. 2009 Jun;4(6):e6079.
|HIV-1 drug resistance mutations: an updated framework for the second decade of HAART|
Shafer RW, Schapiro JM. AIDS Rev. 2008 Apr-Jun;10(2):67-84. Review.
|Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies|
Shafer RW, Rhee SY, Bennett DE. Antivir Ther. 2008;13 Suppl 2:59-68. Review.
|Antiretroviral therapy: optimal sequencing of therapy to avoid resistance|
Martinez-Cajas JL, Wainberg MA. Drugs. 2008;68(1):43-72. Review.
|Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy|
Johnson JA, Li JF, Wei X. PLoS Med. 2008 Jul 29;5(7):e158.
| Guidelines and Best Practices|
| Conference Reports and Proceedings|
| Online Books and Chapters|
| Clinician Support Tools|
| Slide Sets|
| Patient and Community Education|